Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
p-Chlorophenylalanine (HB1647)
Description:Irreversible tryptophan hydroxylase inhibitor. Depletes 5-HT.
Purity:>99%
-
Cyclopamine (HB2965)
Description:Smo and hedgehog (Hh) signaling inhibitor. Also depletes stem like cancer cells and induces hESCs into endocrine cells.
Purity:>98%
- Description:
Inhibits α-MSH release inhibitors. Also increase dopamine levels.
- Description:
LPA1 and LPA2 agonist. Inhibits differentiation of neural stem cells (NSCs) into neurons.
Purity:>95%
